Stock ARDMQ ARADIGM CORPORATION
Add to a list

Aradigm Corporation Share Price

Stocks

ARDMQ

US0385054004

Biotechnology & Medical Research

OTC Markets Traded
Delayed OTC Markets
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for Aradigm Corporation +6.73% -25.81%
29/06/20 Aradigm Corporation Went Out of Business CI
12/06/20 Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation CI

Valuation: Aradigm Corporation

Market Cap 4.89M 4.23M 3.95M 3.61M 6.81M 466M 6.91M 46.35M 18.19M 233M 18.34M 17.94M 776M P/E 2016
-0.72x
P/E 2017 -9.3x
Enterprise Value 12.8M 11.08M 10.36M 9.46M 17.84M 1.22B 18.11M 121M 47.65M 611M 48.06M 47.01M 2.03B EV / Sales 2016
73.3x
EV / Sales 2017 7.27x
Free-Float
60.28%
Yield 2016 *
-
Yield 2017 -
* Estimated data More valuation ratios

Latest news : Aradigm Corporation

29/06/20 Aradigm Corporation Went Out of Business CI
12/06/20 Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation CI
27/04/20 Revised Disclosure Statement Conditionally Approved for Aradigm Corporation CI
08/04/20 Combined Liquidation Plan and Disclosure Statement Filed by Aradigm Corporation CI
30/03/20 Grifols, S.A. completed the acquisition of Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q). CI
30/03/20 Motion for Asset Sale Approved for Aradigm Corporation CI
09/03/20 Bidding Procedure Approved for Aradigm Corporation CI
21/02/20 Motion for Asset Sale Filed by Aradigm Corporation CI
20/02/20 Grifols, S.A. entered into an asset purchase agreement to acquire Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q) for $6.3 million. CI
06/11/19 Second Motion for Exclusivity Period Extension Approved For Aradigm Corporation CI
30/10/19 Aradigm Corporation Announces Withdrawal of European Marketing Authorization Application for Linhaliq CI
21/10/19 Aradigm Corporation Receives Feedback Following an Oral Explanation with the European Medicines Agency CI
19/07/19 Motion for Exclusivity Period Extension Approved For Aradigm Corporation CI
More news

Press Releases: Aradigm Corporation

15/06/20 ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K) AQ
04/06/20 ARADIGM CORP : Other Events (form 8-K) AQ
30/04/20 ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K) AQ
13/04/20 ARADIGM CORP : Other Events (form 8-K) AQ
06/04/20 Aradigm : Announces Sale of Assets to Grifols, S.A. AQ
More press releases

Other Biotechnology & Medical Research

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5-day change 1-year change 3-year change Capi.($)
ARADIGM CORPORATION Stock Aradigm Corporation
-.--%+6.73% - - 702K
LONZA GROUP AG Stock Lonza Group AG
+1.29%+3.46%+6.43%+16.36% 50.03B
REVOLUTION MEDICINES, INC. Stock Revolution Medicines, Inc.
+0.89%+13.44%+491.34%+594.30% 44.36B
BEONE MEDICINES AG Stock BeOne Medicines AG
+3.08%+14.42%+24.57%+81.39% 40.82B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.38%+3.70%+34.54%+9.11% 39.83B
CELLTRION, INC. Stock Celltrion, Inc.
+0.85%+10.32%+21.22%+47.64% 32.51B
ASCENDIS PHARMA A/S Stock Ascendis Pharma A/S
+0.08%+5.00% - - 16.85B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+1.99%+5.08%+38.70%+125.08% 16.81B
EUROFINS SCIENTIFIC SE Stock Eurofins Scientific SE
+0.34%+3.40%+5.39%+18.79% 14.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
+3.56%+19.98%+86.23%+27.29% 13.22B
Average +1.35%+7.26%+88.55%+115.00% 26.85B
Weighted average by Cap. +1.49%+7.09%+107.51%+139.66%
See all sector performances

Financials

2016 2017
Net sales 195K 169K 158K 144K 272K 18.6M 276K 1.85M 726K 9.3M 732K 716K 30.99M 14.46M 12.52M 11.7M 10.7M 20.16M 1.38B 20.47M 137M 53.86M 690M 54.31M 53.13M 2.3B
Net income -32.94M -28.51M -26.65M -24.36M -45.9M -3.14B -46.62M -313M -123M -1.57B -124M -121M -5.23B -10.7M -9.27M -8.66M -7.92M -14.92M -1.02B -15.15M -102M -39.86M -511M -40.2M -39.32M -1.7B
Net Debt -9.37M -8.11M -7.58M -6.93M -13.06M -894M -13.27M -88.93M -34.89M -447M -35.19M -34.42M -1.49B 7.91M 6.85M 6.4M 5.85M 11.03M 755M 11.2M 75.08M 29.46M 378M 29.71M 29.06M 1.26B
* Estimated data More financial data

Company Profile

Logo Aradigm Corporation
Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.
Employees
-
Sector
Biotechnology & Medical Research
More about the company
  1. Stock Market
  2. Stocks
  3. ARDMQ Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong